Evidence map›Paper›PMID 39147127›Full record

ReviewJournal of molecular biology2025

The CDK9-SPT5 Axis in Control of Transcription Elongation by RNAPII.

Rui Sun, Robert P Fisher

Abstract readReview
In one paragraph

Review in Journal of molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rui SunDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Robert P FisherDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA. Electronic address: robert.fisher@mssm.edu.

Funding

Cyclin-dependent kinase control of cell-division and transcription cyclesR35GM127289 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT P FISHER · 2018 to 2026
$4.4M
NIGMS NIH HHS R35 GM127289
6 · The paper itself

Abstract

The RNA polymerase II (RNAPII) transcription cycle is regulated at every stage by a network of cyclin-dependent protein kinases (CDKs) and protein phosphatases. Progression of RNAPII from initiation to termination is marked by changing patterns of phosphorylation on the highly repetitive carboxy-terminal domain (CTD) of RPB1, its largest subunit, suggesting the existence of a CTD code. In parallel, the conserved transcription elongation factor SPT5, large subunit of the DRB sensitivity-inducing factor (DSIF), undergoes spatiotemporally regulated changes in phosphorylation state that may be directly linked to the transitions between transcription-cycle phases. Here we review insights gained from recent structural, biochemical, and genetic analyses of human SPT5, which suggest that two of its phosphorylated regions perform distinct functions at different points in transcription. Phosphorylation within a flexible, RNA-binding linker promotes release from the promoter-proximal pause-frequently a rate-limiting step in gene expression-whereas modifications in a repetitive carboxy-terminal region are thought to favor processive elongation, and are removed just prior to termination. Phosphorylations in both motifs depend on CDK9, catalytic subunit of positive transcription elongation factor b (P-TEFb); their different timing of accumulation on chromatin and function during the transcription cycle might reflect their removal by different phosphatases, different kinetics of phosphorylation by CDK9, or both. Perturbations of SPT5 regulation have profound impacts on viability and development in model organisms through largely unknown mechanisms, while enzymes that modify SPT5 have emerged as potential therapeutic targets in cancer; elucidating a putative SPT5 code is therefore a high priority.

Indexed as

Cyclin-Dependent Kinase 9RNA Polymerase IITranscriptional Elongation FactorsChromosomal Proteins, Non-HistoneHumansNuclear ProteinsPhosphorylationTranscription Elongation, GeneticTranscription, GeneticCDK9 protein, humanChromosomal Proteins, Non-HistoneCyclin-Dependent Kinase 9Nuclear ProteinsRNA Polymerase IISPT5 transcriptional elongation factorSUPT5H protein, humanTranscriptional Elongation Factorscyclin-dependent kinase 9 (CDK9)promoter-proximal pauseRNA polymerase IISpt5transcription elongation

Identifiers

PMID39147127
PMCPMC11649480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.